Trial Profile
A Phase III, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Assess the Relative Efficacy and Tolerability of Two Doses of MK-0663/Etoricoxib in Patients With Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Etoricoxib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Organon
- 22 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 May 2014 Planned End Date changed from 1 Sep 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 25 Apr 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.